Breaking News

Compugen (CGEN) was informed that Bayer (BAYRY) dosed the first patient in the Phase 1 clinical trial of BAY 1905254, a first-in-class immuno-oncology therapeutic antibody targeting the ILDR2 protein, in patients with advanced solid tumors. Under the terms of the collaboration and license agreement, Compugen is entitled to a milestone payment of $7.8M at first patient dosing. ILDR2 is a new immune checkpoint protein identified by Compugen using its predictive target discovery platform.

Compugen announced that the first patient has been dosed in its Phase 1 clinical trial of COM701, a first-in-class cancer immunotherapy antibody targeting PVRIG. PVRIG is a novel immune checkpoint identified by Compugen using its computational discovery capabilities. This Phase 1 open-label clinical trial is designed to assess the safety and tolerability of administering escalating doses of COM701 monotherapy as well as combination administration with a PD-1 inhibitor in patients with advanced solid tumors. Additionally, the trial will evaluate evidence of preliminary antitumor activity of COM701 as a monotherapy as well as in combination with a PD-1 inhibitor in patients with selected tumor types, including non-small cell lung cancer, ovarian cancer, breast cancer and endometrial cancer. The study will be conducted in multiple leading oncology clinical centers in the United States, which are expected to enroll approximately 140 patients.

Compugen (CGEN) announced the appointment of Jean-Pierre Bizzari, M.D., formerly EVP and global head of oncology at Celgene Corporation (CELG), to its Board of Directors. Bizzari is a world-renowned oncology expert who brings to Compugen over 35 years of broad experience in oncology drug development.